Sign inJoin waitlistJoin the waitlist

CH

Christine Hann

Associate Professor of Oncology · New York Presbyterian Hospital

Credentials: · · · ·

History

New York Presbyterian Hospital
Present

Medical Oncology
2003–2005
Internal Medicine
2000–2003
Sidney Kimmel Medical College at Thomas Jefferson University
1996–2000

Research

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma
New England Journal of Medicine · 2009 · 873 citations
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449
Case report · New England Journal of Medicine · 2009 · 822 citations
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma
Science · 2009 · 717 citations

Julie Brahmer
33 papers
PF
Patrick Forde
31 papers
Charles Rudin
29 papers
Kristen Marrone
27 papers
JF
Josephine Feliciano
26 papers
BL
Benjamin Levy
21 papers
DE
David Ettinger
21 papers
VL
Vincent Lam
18 papers
JN
Jarushka Naidoo
17 papers
Valsamo Anagnostou
17 papers
JM
Joseph Murray
16 papers
Gary Gallia
15 papers · 4 as a resident

Grants

Bioinformatic-Chemical Approach to Credential Molecular Targets to Combat Rapid Chemo-Radiation Resistance in SCLC
National Cancer Institute · U01
Contact PI · $3.9M · Johns Hopkins University
2018–2024
The Role of the Tumor Suppressor RhoB in Pulmonary Aging and Lung Tumorigenesis
National Cancer Institute · R21
Contact PI · $387.6K · Johns Hopkins University
2015–2017

Clinical trials

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
Principal investigator · Terminated · Phase 1, Phase 2
National Cancer Institute (NCI)
2018–2022
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Principal investigator · Terminated · Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2018–2021
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2025–2029